Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric McDade

Showing results (61-70 of 194) with videos related to

Pageof 20
Sort By:
Medrxiv : the Preprint Server for Health Sciences|August 7, 2024
The CentiMarker Project: Standardizing Quantitative Alzheimer's disease Fluid Biomarkers for Biologic InterpretationGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
Neuroimage|January 29, 2013
Classification of amyloid-positivity in controls: comparison of visual read and quantitative approachesAnn D Cohen, Wenzhu Mowrey, Lisa A Weissfeld, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 16, 2025
The CentiMarker project: Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretationGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersAleksandra Beric, Wenjing Lin, Gina Jerome, et al.
Alzheimer'S Research & Therapy|May 25, 2023
Tau accumulation in autosomal dominant Alzheimer's disease: a longitudinal [<sup>18</sup>F]flortaucipir studyAntoinette O'Connor, David M Cash, Teresa Poole, et al.
Annals of Neurology|January 26, 2012
Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based studyBrendon P Boot, Bradley F Boeve, Rosebud O Roberts, et al.
Neurology|May 18, 2023
Longitudinal Relationships of White Matter Hyperintensities and Alzheimer Disease Biomarkers Across the Adult Life SpanJingqin Luo, Yinjiao Ma, Folasade Jane Agboola, et al.
Nature Medicine|April 3, 2026
Target product profiles for treatments to delay or prevent symptomatic Alzheimer's diseaseJeffrey L Cummings, Michael G Agadjanyan, Maureen Barry, et al.
Annals of Neurology|July 18, 2018
Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's diseaseYen Ying Lim, Jason Hassenstab, Alison Goate, et al.
Alzheimer'S Research & Therapy|April 10, 2026
Etalanetug (E2814) in dominantly inherited Alzheimer's disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairmentErica Andreozzi, Takuya Yagi, Kristin Wildsmith, et al.
Pageof 20

Showing results (61-70 of 194) with videos related to

Sort By:
Pageof 20
Medrxiv : the Preprint Server for Health Sciences|August 7, 2024
The CentiMarker Project: Standardizing Quantitative Alzheimer's disease Fluid Biomarkers for Biologic InterpretationGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
Neuroimage|January 29, 2013
Classification of amyloid-positivity in controls: comparison of visual read and quantitative approachesAnn D Cohen, Wenzhu Mowrey, Lisa A Weissfeld, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 16, 2025
The CentiMarker project: Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretationGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
BiomarkersAleksandra Beric, Wenjing Lin, Gina Jerome, et al.
Alzheimer'S Research & Therapy|May 25, 2023
Tau accumulation in autosomal dominant Alzheimer's disease: a longitudinal [<sup>18</sup>F]flortaucipir studyAntoinette O'Connor, David M Cash, Teresa Poole, et al.
Annals of Neurology|January 26, 2012
Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based studyBrendon P Boot, Bradley F Boeve, Rosebud O Roberts, et al.
Neurology|May 18, 2023
Longitudinal Relationships of White Matter Hyperintensities and Alzheimer Disease Biomarkers Across the Adult Life SpanJingqin Luo, Yinjiao Ma, Folasade Jane Agboola, et al.
Nature Medicine|April 3, 2026
Target product profiles for treatments to delay or prevent symptomatic Alzheimer's diseaseJeffrey L Cummings, Michael G Agadjanyan, Maureen Barry, et al.
Annals of Neurology|July 18, 2018
Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's diseaseYen Ying Lim, Jason Hassenstab, Alison Goate, et al.
Alzheimer'S Research & Therapy|April 10, 2026
Etalanetug (E2814) in dominantly inherited Alzheimer's disease: an open-label phase 1b/2 study to assess safety and target engagement in participants with mild to moderate cognitive impairmentErica Andreozzi, Takuya Yagi, Kristin Wildsmith, et al.
Pageof 20